Persevere's Power Play: Tapping a Biotech Veteran for its 'Undruggable' Drug

CHESTERBROOK, PA – August 31, 2026 – In a move that speaks volumes about its strategic ambitions, clinical-stage oncology company Persevere Therapeutics has appointed James (Jim) Barlow to its Board of Directors. While board appointments are routine, the timing and the appointee’s track record signal a calculated power play by the firm as it enters the most critical—and capital-intensive—phase of its journey to tame one of cancer’s most formidable targets.

The appointment coincides with two major inflection points for the company: the initiation of a Phase 2a clinical trial for its lead asset, misetionamide, in platinum-resistant ovarian cancer, and its selection as a finalist for a major grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund a separate trial in pancreatic cancer. For a private biotech, this is the moment where promising science must be paired with flawless execution and deep financial resources. In bringing on Barlow, Persevere is betting on a leader who has written the playbook for this exact scenario.

A "Proven Playbook" for a Pivotal Moment

James Barlow is not just another experienced executive; he is a specialist in transforming early-stage biotech ventures into clinical and financial successes. His resume reads like a blueprint for the path Persevere is now treading. As President and CEO of ImmunoGenesis, he took a foundational concept from MD Anderson Cancer Center and built it into a clinical-stage company, raising over $110 million in a complex mix of dilutive and non-dilutive capital. This included successfully navigating the highly competitive CPRIT grant process twice—a feat Persevere now aims to replicate.

"Jim's appointment comes at an exciting and pivotal moment for Persevere," said Greg Bosch, Chairman and Chief Executive Officer of Persevere Therapeutics, in a statement. "Jim has done exactly what we are setting out to do — built a company from the ground up, raised capital creatively, advanced assets into the clinic, and navigated the complex intersection of science, finance, and strategy in oncology."

Barlow’s experience extends beyond fundraising. At Geneos Therapeutics, he was instrumental in spinning the company out of Inovio Pharmaceuticals and driving its first asset from financing to an Investigational New Drug (IND) application in under nine months. His earlier career at Bristol Myers Squibb and Merck saw him on the front lines of commercial strategy for blockbuster oncology drugs like YERVOY® and OPDIVO®. This blend of startup agility, capital formation acumen, and big pharma commercial insight makes him a uniquely valuable asset for a company like Persevere, which must simultaneously manage its science, its finances, and its long-term market strategy.

The High-Stakes Bet on Cracking MYC

At the heart of Persevere's strategy is its drug, misetionamide, a first-in-class inhibitor targeting MYC. For decades, MYC has been known as 'the grand orchestrator of cancer growth,' a master regulator protein that, when dysregulated, drives the proliferation of a vast number of human cancers. Yet it has remained stubbornly 'undruggable.' Lacking the well-defined pockets that traditional small-molecule drugs bind to, MYC’s disordered structure has thwarted countless drug discovery efforts, making it one of oncology's most sought-after but elusive targets.

Persevere's claim that misetionamide can inhibit MYC represents a significant scientific bet. If successful, it could unlock a new paradigm in cancer treatment. The company is initially targeting two cancers with dire prognoses and high unmet needs: platinum-resistant ovarian cancer and pancreatic cancer. In ovarian cancer, patients who become resistant to platinum-based chemotherapy have few effective options, with low response rates to subsequent treatments. Similarly, pancreatic cancer remains one of the most lethal malignancies, largely resistant to both chemotherapy and modern immunotherapies.

By targeting a fundamental driver like MYC, misetionamide could potentially offer a new line of attack where other therapies have failed. The completion of a 55-patient Phase 1 trial has provided the company with the safety data needed to advance into Phase 2, where the drug's efficacy will be put to the test. Barlow's appointment is a clear vote of confidence in the underlying science. "I am honored to join the Persevere Board at such an exciting juncture," Barlow stated. "Misetionamide represents a potentially transformational therapy for cancer patients."

Navigating the Clinical and Financial Gauntlet

With its 'MIROC-1' Phase 2a trial now launching at four U.S. clinical sites for ovarian cancer, Persevere is officially entering a more advanced stage of clinical development. These mid-stage trials are substantially more complex and expensive than Phase 1 studies, requiring a robust operational and financial foundation. This is where the company's dual-pronged strategy—advancing its lead program while securing major non-dilutive funding—becomes critical.

The company's status as a 2026 CPRIT Finalist is a significant validation of its pancreatic cancer program. The Texas-based institute is known for its rigorous, multi-stage peer-review process that vets both the scientific merit and the commercial potential of applicants. Being named a finalist means Persevere's proposal has already been deemed highly competitive by scientific and business experts. Securing the grant, which can amount to tens of millions of dollars for product development, would provide a substantial financial runway and de-risk the pancreatic cancer program without diluting current shareholders.

This is precisely the type of strategic financing that Barlow mastered at ImmunoGenesis. His experience in securing CPRIT funding provides Persevere with invaluable institutional knowledge of the process, potentially increasing its odds of success. For a privately held company with limited public financial disclosures, securing such a grant would be a transformative event, enabling it to aggressively pursue two Phase 2 programs in parallel and significantly increasing its value proposition to future partners and investors.

A Calculated Move in a Competitive Field

The oncology landscape is fiercely competitive, but Persevere Therapeutics appears to be carving out a unique niche. While other companies are developing novel antibody-drug conjugates and immunotherapies for ovarian and pancreatic cancer, a direct, first-in-class MYC inhibitor would be a truly disruptive force. It offers a mechanism of action completely distinct from existing standards of care, holding the potential to overcome the resistance that plagues so many current treatments.

The addition of an industry veteran like Barlow is a strategic signal to the market, potential partners, and investors. It demonstrates that the company is bolstering its leadership with the expertise needed to navigate the path to commercialization. His role will likely extend beyond typical board governance to actively helping shape clinical strategy, guide capital formation, and build the corporate infrastructure necessary to support late-stage development. This move reinforces that Persevere is thinking not just about the next clinical data readout, but about building a sustainable enterprise. For Persevere Therapeutics, the addition of James Barlow is a clear signal that its mission is not just to innovate in the lab, but to execute a strategy that can survive the demanding journey from clinical trial to patient bedside.